A double-blind dose-finding pilot study of docosahexaenoic acid (DHA) for major depressive disorder

作者：Mischoulon D^*; Best Popescu C; Laposata M; Merens W; Murakami J L; Wu S L; Papakostas G I; Dording C M; Sonawalla S B; Nierenberg A A; Alpert J E; Fava M

来源：European Neuropsychopharmacology, 2008, 18(9): 639-645.

DOI：10.1016/j.euroneuro.2008.04.011

• Depression
• DHA
• Docosahexaenoic acid
• Eicosapentaenoic acid
• EPA
• n-3
• Omega-3

We examined the antidepressant efficacy and dose-response pattern of the n-3 docosahexaenoic acid (DHA). Thirty-five depressed adult outpatients (46 women; mean age 42 ± 14 years) with a 17-item Hamilton-Depression Scale (HAM-D-17) score of > /= 18 were randomized into one of three double-blind dosing arms for 12 weeks. Group A (n = 14): 1 g/day of oral DHA; Group B (n = 11): 2 g/day; and Group C (n = 10): 4 g/day. We measured HAM-D-17 scores, plasma DHA, eicosapentaenoic acid (EPA), and n-6/n-3 ratio. Completer response rates (> /= 50 decrease in HAM-D-17 score) were 83 for Group A, 40 for Group B, and 0 for Group C; Groups A and B had significant decreases in HAM-D-17 scores (p < 0.05). For completers and intent-to-treat subjects, plasma DHA increased significantly (p < 0.05), EPA had little change (p > 0.05), and n-6/n-3 decreased significantly (p < 0.05). DHA may be effective for depression at lower doses.

• 单位
  harvard medical school